NASDAQ: NPCENeuropace Inc Stock
$11.69-0.29 (-2.42%)
Updated Apr 30, 2025
NPCE Price
$11.69
Fair Value Price
N/A
Market Cap
$380.63M
52 Week Low
$5.45
52 Week High
$15.11
P/E
-12.57x
P/B
47.5x
P/S
4.08x
PEG
N/A
Dividend Yield
N/A
Revenue
$79.91M
Earnings
-$27.14M
Gross Margin
73.9%
Operating Margin
-22.96%
Profit Margin
-34%
Debt to Equity
10.81
Operating Cash Flow
-$18M
Beta
0.93
Next Earnings
Jun 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
NPCE Overview
NeuroPace, Inc. develops and sells a brain-responsive neuromodulation system that treats epilepsy. The system records continuous brain activity data, enabling clinicians to monitor patients in person and remotely. NeuroPace was incorporated in 1997 and is headquartered in Mountain View, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NPCE's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
NPCE
Ranked#37 of 108
Ranked#37 of 108
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.31 | A | |
| $23.03 | A | |
| $14.12 | A |
Be the first to know about important NPCE news, forecast changes, insider trades & much more!
NPCE News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NPCE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NPCE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NPCE is poor value based on its book value relative to its share price (47.5x), compared to the US Medical Devices industry average (3.94x)
P/B vs Industry Valuation
NPCE is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NPCE due diligence checks available for Premium users.
Valuation
NPCE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-12.57x
Industry
37.39x
Market
29.18x
NPCE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
47.5x
Industry
3.94x
NPCE is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NPCE's financial health
Profit margin
Revenue
$21.5M
Net Income
-$5.3M
Profit Margin
-24.5%
NPCE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
NPCE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$94.6M
Liabilities
$86.6M
Debt to equity
10.81
NPCE's short-term assets ($81.34M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NPCE's short-term assets ($81.34M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NPCE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NPCE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.8M
Investing
$2.0M
Financing
$848.0k
NPCE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NPCE vs Medical Device Stocks
Neuropace Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.